Alert
|
1 microgram = 1000 nanograms.
|
Indication
|
For temporary maintenance of ductus arteriosus patency until corrective or palliative surgery can be performed in neonates with ductal-dependent congenital heart defects.
|
Action
|
Relaxes the ductus arteriosus in early postnatal life and supports its patency.
|
Drug Type
|
Prostaglandin E1 or PGE1
|
Trade Name
|
Prostin VR.
|
Presentation
|
Ampoules (sterile solution) 500 microgram/mL 1 mL
|
Dosage / Interval
|
Starting Dose
Dose: 10 nanogram/kg/minute (range: 5 to 50 nanogram/kg/minute).
For known congenital heart disease patients and prior to ductal closure: Start at 10 nanogram/kg/min.
If there is no clinical or echocardiographic response to the maximum dose of 50 nanogram/kg/min, then consult a paediatric cardiologist. Very rarely they may suggest a very short trial of up to 100 nanogram/kg/min.
Maintenance Dose
3-20 nanogram/kg/minute. Aim is to be on the lowest dose that safely maintains ductal patency.
|
Maximum dose
|
Higher doses ≥50 nanogram/kg/minute may be needed to resuscitate infants with poor perfusion and oxygenation (‘grey baby’) and with ductal closure in suspected duct-dependent congenital heart disease.
|
Route
|
Continuous IV infusion.
|
Preparation/Dilution
|
LOW concentration continuous IV infusion [use if attempting to avoid ventilation and keep ductus open]
Infusion strength
|
Prescribed amount
|
1 mL/hour = 10 nanogram/kg/minute
|
30 microgram/kg alprostadil (Prostin VR, PGE1) and make up to 50 mL
|
First dilution: Draw up 1 mL (500 microgram) of alprostadil and add 9 mL of sodium chloride 0.9% or glucose 5% to make a final volume of 10 mL with a concentration of 50 microgram/mL.
Second dilution: From this, draw up 0.6 mL/kg (30 microgram/kg) and dilute to 50 mL with sodium chloride 0.9% or glucose 5%. Infuse at rate of 1 mL/h = 10 nanogram/kg/minute.
HIGH concentration continuous IV infusion [consider if ductus closed and/or mechanically ventilated]
Infusion strength
|
Prescribed amount
|
1 mL/hour = 50 nanogram/kg/minute
|
150 microgram/kg alprostadil (Prostin VR, PGE1) and make up to 50 mL
|
First dilution: Draw up 1 mL (500 microgram of alprostadil) and add 9 mL of sodium chloride 0.9% or glucose 5% to make a final volume of 10 mL with a concentration of 50 microgram/mL.
Second dilution: From this, draw up 3 mL/kg (150 microgram/kg) and dilute to 50 mL with sodium chloride 0.9% or glucose 5%. Infusing at rate of 1 mL/h = 50 nanogram/kg/minute.
|
Administration
|
Continuous intravenous infusion. Ensure reliable intravenous access as short half-life.
|
Monitoring
|
Continuous pulse oximetry, heart rate, ECG and blood pressure monitoring.
Assess urine output and peripheral perfusion frequently.
|
Contraindications
|
|
Precautions
|
Ensure adequate cardiorespiratory monitoring and cardiorespiratory resuscitation equipment available for immediate use if necessary.
Apnoea is frequent. Commencement of alprostadil ≤ 20 nanogram/kg/min and low maintenance dose reduces apnoea incidence.
Titrate to infant’s response (increased oxygenation, echo findings and side effects) - Aim is to be on the lowest dose that safely maintains the ductal patency.
Hyperosmolar – infuse at concentrations < 20 microgram/mL.
Neonates with total anomalous pulmonary venous return below the diaphragm – may precipitate pulmonary oedema because of increased pulmonary blood flow.
|
Drug Interactions
|
Concomitant administration with heparin may result in an increased risk of bleeding.
|
Adverse Reactions
|
Apnoea is frequent. Commencement of alprostadil ≤ 20 nanogram/kg/min and low maintenance dose reduces apnea incidence. Methylxanthines (caffeine or aminophylline) may be used to prevent or treat apnoea. [4]
May lower blood pressure by relaxing the vascular smooth muscle causing vasodilatation and can elevate body temperature.
Other reported effects include abdominal distension, bradycardia, enterocolitis, vomiting and skin rash. [5]
With prolonged use, skeletal changes [10] and hypertrophic pyloric stenosis [11, 12] have been reported.
Extravasation may cause tissue necrosis.
|
Compatibility
|
Fluids: Glucose 5%, sodium chloride 0.9%.
Y-site: Amino acid solutions, ampicillin; cefazolin; cefotaxime; chlorothiazide; dobutamine; dopamine; fentanyl; gentamicin; methylprednisolone; nitroprusside; potassium chloride; tobramycin, vancomycin; vecuronium.
Syringe: Caffeine; dobutamine; dopamine; adrenaline (epinephrine); fentanyl; midazolam; morphine.
|
Incompatibility
|
Y-site: Levofloxacin
|
Stability
|
Diluted solution stable for up to 24 hours.
|
Storage
|
Ampoule: Store at 2 to 8°C. Do not freeze.
|
Special Comments
|
Do not use if cloudy (crystallised).
Undiluted solution (500 microgram/mL) is hyperosmolar. Dilute before administration to a concentration of 20 microgram/mL or less.
|
Evidence summary
|
Efficacy:
|
